Pre-approval Information Exchange Act of 2022
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Mar 9, 2022)
Pre-approval Information Exchange Act of 2022
This bill specifies that economic, scientific, or other product support information that is exchanged between drug manufacturers and health care entities (e.g., pharmacy benefit managers) about drug products before regulatory approval is not considered to be misbranding or prohibited premarket promotion if it relates to the product's investigational use and meets other specified criteria. The Government Accountability Office must study the use and effects of such information.
What just happenedMar 10, 2022
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseMar 9, 2022
- Mar 10, 2022Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Mar 9, 2022IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Mar 9, 2022IntroReferralIntro-H
Introduced in House
- Mar 9, 2022IntroReferral1000
Introduced in House